<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Canadian Medicine &#187; chemotherapy</title>
	<atom:link href="http://www.canadianmedicine4all.com/tag/chemotherapy/feed" rel="self" type="application/rss+xml" />
	<link>http://www.canadianmedicine4all.com</link>
	<description></description>
	<lastBuildDate>Thu, 26 Jan 2012 08:54:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.1.2</generator>
		<item>
		<title>Interscience Conference on Antimicrobial Agents and Chemotherapy: Peginterferon alfa-2a plus Ribavirin in Patients  with HIV and HCV Co-infection</title>
		<link>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-peginterferon-alfa-2a-plus-ribavirin-in-patients-with-hiv-and-hcv-co-infection.html</link>
		<comments>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-peginterferon-alfa-2a-plus-ribavirin-in-patients-with-hiv-and-hcv-co-infection.html#comments</comments>
		<pubDate>Fri, 07 May 2010 10:36:53 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Interscience Conference]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=1729</guid>
		<description><![CDATA[Speaker: Douglas T. Dieterich, MD, Vice Chair and Chief Medical Officer, Department of Medicine, and Professor of Medicine, Mount Sinai Medical Center, New York, New York Patients who are co-infected with HIV and hepatitis C virus (HCV) who achieve a sustained virological response with peginterferon alfa-2a (Pegasys®, Roche) and ribavirin generic (Rebe-tol®, Schering) combination therapy [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-peginterferon-alfa-2a-plus-ribavirin-in-patients-with-hiv-and-hcv-co-infection.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interscience Conference on Antimicrobial Agents and Chemotherapy: Tipranavir-Based Regimen Valuable in Treatment-Experienced Patients with HIV Infection</title>
		<link>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-tipranavir-based-regimen-valuable-in-treatment-experienced-patients-with-hiv-infection.html</link>
		<comments>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-tipranavir-based-regimen-valuable-in-treatment-experienced-patients-with-hiv-infection.html#comments</comments>
		<pubDate>Thu, 06 May 2010 10:36:52 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Interscience Conference]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=1728</guid>
		<description><![CDATA[Speaker: Charles Hicks, MD, Associate Professor of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina Tipranavir (TPV) (Boehringer Ingelheim), a novel non-peptidic protease inhibitor (PI), now in late phase 3 clinical development, plus low-dose ritonavir(r) (Norvir drug, Abbott) was found to be significantly superior to currently available comparator protease inhibitors (CPIs) [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-tipranavir-based-regimen-valuable-in-treatment-experienced-patients-with-hiv-infection.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interscience Conference on Antimicrobial Agents and Chemotherapy: Reduced Risk of Pneumonia in Influenza Patients Treated with Oseltamivir</title>
		<link>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-reduced-risk-of-pneumonia-in-influenza-patients-treated-with-oseltamivir.html</link>
		<comments>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-reduced-risk-of-pneumonia-in-influenza-patients-treated-with-oseltamivir.html#comments</comments>
		<pubDate>Wed, 05 May 2010 10:36:51 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Interscience Conference]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=1727</guid>
		<description><![CDATA[Speaker: Beth L. Nordstrom, PhD, Epidemiologist, Ingenix Epidemiology, Aburndale, Massachusetts In a large population of patients with influenza, treatment with oseltamivir (Drug Tamiflu, Hoffman-LaRoche Ltd.) was associated with a significant reduction in the risk of pneumonia. Several clinical studies showed that oseltamivir was up to 92% effective in preventing influenza in adolescents, adults, and elderly [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy-reduced-risk-of-pneumonia-in-influenza-patients-treated-with-oseltamivir.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Interscience Conference on Antimicrobial Agents and Chemotherapy</title>
		<link>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy.html</link>
		<comments>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy.html#comments</comments>
		<pubDate>Tue, 04 May 2010 11:01:24 +0000</pubDate>
		<dc:creator>David</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Antimicrobial Agents]]></category>
		<category><![CDATA[chemotherapy]]></category>
		<category><![CDATA[Interscience Conference]]></category>

		<guid isPermaLink="false">http://www.canadianmedicine4all.com/?p=1726</guid>
		<description><![CDATA[Single-Dose Azithromycin Microsphere Formulation for Acute Exacerbation of Chronic Bronchitis Speaker: Marcus J. Zervos, MD, Infectious Diseases Specialist, William Beaumont Hospital, Royal Oak, Michigan, and Wayne State University School of Medicine, Detroit, Michigan A single dose of a novel formulation of azithromycin micro-spheres (Pfizer) has proved to be as effective as a seven-day course of [...]]]></description>
		<wfw:commentRss>http://www.canadianmedicine4all.com/interscience-conference-on-antimicrobial-agents-and-chemotherapy.html/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

